InMed Pharmaceuticals develops technology to bridge the gap between synthetic and natural cannabinoids. This Vancouver based biotech company uses an E. coli-based expression system to develop a biosynthesis process utilizing cannabinoid DNA that is identical to those found in nature.
The company is the world’s first known company to take advantage of this biosynthesis manufacturing technique to create a biosynthetic cannabinoid for the treatment of glaucoma. InMed has formulated a hydrogel as a drug delivery system for the eye condition using these cannabinoids. Normally, when a patient has glaucoma, they must use eye drops multiple times per day, but with the company’s medicated hydrogel they only need to apply it once before bed. InMed’s pharmaceutical-grade biosynthetic cannabinoids are identical to those found in nature and are more than 95% pure, without any mind-altering properties, such as tetrahydrocannabinol (THC), that are naturally found in a cannabis plant.
Earlier this week, InMed announced that a study co-sponsored by the University of British Columbia has shown an enhanced drug uptake of the hydrogel-mediated cannabinoid nanoparticle delivery to the eye via the cornea and lens.
READ FULL ARTICLE AT BIOTECHNOLOGY FOCUS
Read More
Biosynthetic cannabinoids could be the way of the future
